Compare Merck & Co., Inc. (MRK) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Otis Worldwide Corp — how do they compare? Merck & Co., Inc. trades at $133.35 (market cap $327.94B), while Otis Worldwide Corp trades at $74.32 (market cap $28.16B). The key difference: Merck & Co., Inc. is far larger — about 11.6× Otis Worldwide Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| MRK | OTIS | |
|---|---|---|
Market Cap | $327.94B | $28.16B |
Sector | Health | Industrials |
52-Week High | $132.93 | $93.62 |
52-Week Low | $77.60 | $69.34 |
Enterprise Value | $374.70B | $36.19B |
Dividend Yield | 2.56% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $65.01B in 2025 with net income of $18.25B, though 2026 projections show lower profitability. Recent acquisition activity includes the $6.7B tender offer for Terns Pharmaceuticals to bolster oncology pipeline.
Merck maintains solid fundamentals with 67.6% analyst buy ratings and $140.58 consensus target, offering 7.8% upside. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The stock presents a balanced opportunity with strong institutional support but faces margin compression headwinds in 2026.
Otis Worldwide (OTIS) trades at $73.82, up 1.3% for the day, with a neutral technical signal. Recent Q2 2026 earnings showed a beat on EPS but included guidance cuts, reflecting margin pressures from labor costs. The company maintains strong service segment growth, with modernization revenue up 24%, though new equipment demand remains weak. Cash flow trends show variability, with 2025 net cash flow negative $1.22 billion due to financing activities, while 2026 projects a positive $146 million.
The investment outlook is mixed; analyst consensus is a Buy with a $92.50 price target, implying significant upside, but risks include persistent margin compression and economic sensitivity. The stock's current valuation below historical averages presents a potential opportunity if service margins stabilize and growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
